Research programme: rheumatoid arthritis therapy - Aphoenix

Drug Profile

Research programme: rheumatoid arthritis therapy - Aphoenix

Alternative Names: AFX 001 series; AFX-200 series; Rheumatoid arthritis therapy research programme - Aphoenix

Latest Information Update: 07 Mar 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aphoenix
  • Class Small molecules
  • Mechanism of Action Cytokine inhibitors; Osteoclast inhibitors; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 28 Jun 2005 Aphoenix has completed preclinical trials in Rheumatoid arthritis in Japan
  • 28 Jun 2004 AFX 001 series is available for partnering (
  • 28 Jun 2004 Preclinical trials in Rheumatoid arthritis in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top